Table 1.

Sample characteristics, overall and by assigned PD severity (LED >1000 mg/day algorithm)^a, ^b.

Characteristic	Overall (N = 144,703)		Mild-Moderate PD (n = 115,729)		Advanced PD (n = 28,974)
	N	Percent	N	Percent	N	Percent
Age, years
65–69	16,702	11.5%	11,964	10.3%	4738	16.4%
70–74	27,882	19.3%	20,685	17.9%	7197	24.8%
75–79	33,141	22.9%	26,039	22.5%	7102	24.5%
≥80	66,978	46.3%	57,041	49.3%	9937	34.3%
Sex
Male	70,127	48.5%	53,321	46.1%	16,806	58.0%
Race
White	126,830	87.6%	100,878	87.2%	25,952	89.6%
Black	6666	4.6%	5860	5.1%	806	2.8%
Other	11,207	7.7%	8991	7.8%	2216	7.6%
Region
Northeast	28,430	19.6%	23,061	19.9%	5369	18.5%
Midwest	38,687	26.7%	30,487	26.3%	8200	28.3%
South	52,885	36.5%	43,040	37.2%	9845	34.0%
West	24,701	17.1%	19,141	16.5%	5560	19.2%
RxHCC score, mean (SD)c	1.48 (0.46)		1.50 (0.46)		1.40 (0.45)
Neurologist visitd	101,146	69.9%	76,762	66.3%	24,384	84.2%

PD, Parkinson's disease; RxHCC score, prescription drug hierarchical condition category risk score.

^aPatients were classified based on an algorithm derived from prescription claims. Patients with any 30-day average levodopa equivalent dose (LED) >1000 mg/day were classified as advanced; all others were assigned mild-moderate status.

^bComparisons of patient subgroups for all variables listed were statistically significant at the P < 0.001 level, using chi-square tests for categorical variables and a t-test for the continuous variable.

^cRxHCC scores in the overall sample ranged from 0.72 to 6.30; scores in the mild/moderate PD group ranged from 0.72 to 6.30 and scores in the APD group ranged from 0.72 to 5.33.

^dIndicates patient had an outpatient claim for a neurologist visit during the study year.